![Long-Acting Muscarinic Receptor Antagonists (LAMA) in Clinical Development | Download Scientific Diagram Long-Acting Muscarinic Receptor Antagonists (LAMA) in Clinical Development | Download Scientific Diagram](https://www.researchgate.net/publication/347420613/figure/tbl1/AS:986275486109704@1612157808803/Long-Acting-Muscarinic-Receptor-Antagonists-LAMA-in-Clinical-Development.png)
Long-Acting Muscarinic Receptor Antagonists (LAMA) in Clinical Development | Download Scientific Diagram
![PDF) Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease | brian leaker - Academia.edu PDF) Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease | brian leaker - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/97271440/mini_magick20230114-1-l511sy.png?1673688925)
PDF) Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease | brian leaker - Academia.edu
![Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease - Roy A. Pleasants, 2019 Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease - Roy A. Pleasants, 2019](https://journals.sagepub.com/cms/10.1177/1060028018798753/asset/images/large/10.1177_1060028018798753-fig2.jpeg)
Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease - Roy A. Pleasants, 2019
Nebulized glycopyrrolate shows real-world decrease in exacerbations and hospitalizations in patients with COPD
![PDF) Dose selection for glycopyrrolate/eFlow® phase III clinical studies: Results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies PDF) Dose selection for glycopyrrolate/eFlow® phase III clinical studies: Results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies](https://i1.rgstatic.net/publication/321509214_Dose_selection_for_glycopyrrolateeFlowR_phase_III_clinical_studies_Results_from_GOLDEN_Glycopyrrolate_for_Obstructive_Lung_Disease_via_Electronic_Nebulizer_phase_II_dose-finding_studies/links/5a2628024585155dd4216ffc/largepreview.png)
PDF) Dose selection for glycopyrrolate/eFlow® phase III clinical studies: Results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
![Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease | Cleveland Clinic Journal of Medicine Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease | Cleveland Clinic Journal of Medicine](https://www.ccjm.org/content/ccjom/85/2_suppl_1/S19/F1.large.jpg)
Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease | Cleveland Clinic Journal of Medicine
![Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease - Leaker - 2015 - British Journal of Clinical Pharmacology - Wiley Online Library Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease - Leaker - 2015 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/2997e66e-d175-4a26-b961-da3c9d4f7b17/bcp12517-fig-0001-m.jpg)